The studies also show that ACE-536 promotes red blood formation in the lack of EPO signaling, through an independent pathway. Moreover, ACE-536 has distinct results from EPO on reddish colored blood cell differentiation, and acts on a different human population of progenitor blood cells throughout a later phase of red blood cell development.. Acceleron Pharma’s ACE-536 stimulates red bloodstream cell creation through novel mechanism Acceleron Pharma, Inc., a biopharmaceutical firm developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscles, excess fat, and the vasculature, provided data demonstrating that ACE-536 promotes formation of reddish colored blood cells through inhibition of members of the TGF-beta superfamily, at the 51st Annual Getting together with of the American Culture of Hematology.D., Chief Scientific Officer of Acceleron Pharma.The scholarly study met its major endpoint and, based on these total results, Alba provides initiated planning Phase III medical trials for the definitive assessment of the oral peptide's safety and efficacy. The final data will be submitted for publication soon. The double-blind, placebo-controlled study evaluated the efficacy and security of larazotide acetate in the treating 342 individuals with CeD who acquired persistent symptoms despite getting on a gluten-free diet. Murray, MD, the Phase IIb research's lead investigator and a gastroenterologist at the Mayo Clinic. These promising trial results contribute to an evergrowing body of data supporting the advancement of larazotide acetate, and the medical community looks forwards to its continued advancement in an effort to provide an option to patients who struggle to manage the condition through diet alone.